Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492355 · ClinicalTrials.gov registry record · Phase 1
TP-3654 Food Effect Study
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07492355: Completed Phase 1 study, sponsored by Sumitomo Pharma America.
NCT07492355 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07492355, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This clinical trial will determine the bioavailability and effect of food on TP-3654 in healthy adult participants.
Primary Outcome
Analysis of the maximum concentration (Cmax) of the relative bioavailability of TP-3654 in two different capsule formulations utilizing the ratio of adjusted geometric means
Interventions
- DRUG TP-3654
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 1 |
What the finished NCT07492355 record still lists
NCT07492355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which TP-3654 is the first listed.
NCT07492355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07492355 about?
NCT07492355 is a clinical study titled "TP-3654 Food Effect Study". This clinical trial will determine the bioavailability and effect of food on TP-3654 in healthy adult participants.
What is the current status of trial NCT07492355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-03-04. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT07492355?
The interventions under investigation include: TP-3654 (DRUG).
Who is sponsoring clinical trial NCT07492355?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07492355's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI